Juan L. Pena-Ruiz

Sevilla, AN 41009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Journal: CNS drugs

Published: July 17, 2025

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study.

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study.

Journal: Frontiers in neurology

Published: November 30, 2022

Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital.

Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital.

Journal: Neurology. Clinical practice

Published: March 01, 2021

Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.

Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.

Journal: Multiple sclerosis and related disorders

Published: January 03, 2020

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients.

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients.

Journal: PloS one

Published: October 31, 2018

Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab

Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab

Journal: Revista de neurologia

Published: May 24, 2018

Retest reliability of individual alpha ERD topography assessed by human electroencephalography.

Retest reliability of individual alpha ERD topography assessed by human electroencephalography.

Journal: PloS one

Published: May 25, 2017

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.

Journal: PloS one

Published: July 01, 2016

Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.

Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.

Journal: Journal of the neurological sciences

Published: July 27, 2015

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

Journal: Human molecular genetics

Published: March 01, 2015

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands.

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 01, 2014

Neural correlates of alerting and orienting impairment in multiple sclerosis patients.

Neural correlates of alerting and orienting impairment in multiple sclerosis patients.

Journal: PloS one

Published: December 29, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026